Related Experiment Video
Updated: Jan 17, 2026
Electrophoretic Delivery of γ-aminobutyric Acid GABA into Epileptic Focus Prevents Seizures in Mice
Published on: May 16, 2019
Navigating regulatory challenges in pediatric epilepsy pharmacotherapy: pathways to safe and effective treatments
Gianmichele Villano1, Gianluca D'Onofrio1, Antonella Riva1,2
1Department of Neurosciences Rehabilitation, Ophthalmology, Genetics, Maternal and Child Health (DiNOGMI), University of Genoa, Genoa, Italy.
Insights
Pediatric epilepsy drug development faces challenges due to high costs and regulatory hurdles. A science-driven approach optimizing incentives is crucial for developing new antiseizure medications (ASMs) for children.
Area of Science:
- Neurology
- Pharmacology
- Regulatory Science
Background:
- Epilepsy is a common childhood neurologic condition, yet children are often 'therapeutic orphans' in drug development.
- Developing new antiseizure medications (ASMs) for pediatric populations presents significant financial and regulatory challenges.
- Commercial interest in developing new ASMs is declining due to perceived risks and funding issues.
Purpose of the Study:
- To review the historical context of pediatric epilepsy drug development.
- To analyze current regulatory frameworks and incentives from the US Food and Drug Administration (FDA) and European Medicines Agency (EMA) for ASMs.
- To identify strategies for accelerating the development of innovative epilepsy treatments for children.
Main Methods:
- A narrative review approach was employed.
- Literature searches were conducted across PubMed, EMBASE, Scopus, and Google Scholar using relevant keywords.
- Official FDA and EMA websites and documents were also systematically screened.
Main Results:
- The review traces the evolution of pediatric drug development in epilepsy.
- Current FDA and EMA regulatory frameworks and incentives influencing ASM approval for children were analyzed.
- The study highlights the critical need for optimizing incentives to meet pediatric needs.
Conclusions:
- A more focused, science-driven approach, minimizing nonscientific influences, can accelerate epilepsy treatment innovation.
- Aligning research incentives with specific pediatric epilepsy syndromes and age-appropriate pharmacology is essential.
- Addressing the challenges in pediatric drug development is vital for improving outcomes in childhood epilepsy.
Introduction:
Drug development for epilepsy, the most frequent chronic neurologic childhood condition, faces fundamental challenges. One of these is the concept of children as 'therapeutic orphans' and the resulting pediatric requirements of the US Food and Drug Administration (FDA) and the European Medicines Agency (EMA). Developing new antiseizure medications (ASMs) is expensive. Public coffers and reimbursement institutions are increasingly struggling with fundings. Commercial drug developers are progressively skeptical about the risks of developing new ASMs, which makes a critical review of pediatric requirements even more important.
Areas Covered:
This narrative review traces the roots of pediatric drug development in epilepsy and analyses the current FDA and EMA regulatory frameworks and incentives that shape ASMs approval for children. PubMed, EMBASE, Scopus and Google Scholar were searched for publications using combinations of terms related to 'pediatric epilepsy,' 'antiseizure medications,' 'regulatory frameworks' and 'pediatric drug development.' Official FDA, EMA websites and documents were also screened.
Expert Opinion:
A more focused and science-driven approach, less influenced by nonscientific factors and emerging conflicts of interest, could help accelerate the development of innovative treatments for epilepsy. Optimizing incentives to align research with true pediatric needs, especially those targeting childhood-specific syndromes and age-appropriate pharmacology, is essential.
More Related Videos
09:57Author Spotlight: Advancing Pediatric Epilepsy Surgery in Children Through Novel Biomarkers and Enhanced Localization
Published on: September 20, 2024
08:04Identification and Classification of Position-specific GABAA Receptor Subunit Missense Variants for Their Role In Hippocampal Pyramidal Neurons
Published on: June 6, 2025
Related Concept Videos
01:26Pharmacokinetics in Pediatric Patients: Drug Excretion
01:24Pharmacokinetics in Pediatric Patients: Drug Metabolism
01:17Pharmacokinetics in Pediatric Patients: Drug Distribution
01:23Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption
01:24Epilepsy and Seizures: Overview
Various factors can trigger epilepsy, including genetic factors, brain damage, metabolic causes, and unknown etiology. Diagnosis of epilepsy involves electroencephalography (EEG), which...
01:20Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...